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the tumor is located in a deep position. In the present case, HCC in S4 was diagnosed with CE-US, but not with EOB-MRI. In the present case, many space-occupying lesions (SOL) were detected, and it was difficult to distinguish these SOL from the hepatic adenoma. On CE-US with perflubutane, only the tumor in the 4th segment was detected in the late phase. On the other hand, in the hepatic phase of EOB-MRI, the tumor in the 4th segment was not different from the other tumors. These results suggest that if a SOL is located in a site that is easy to observe by CE-US, then CE-US can provide a more accurate diagnosis than EOB-MRI. The advantage of CE-US using perflubutane is the ability to undertake continuous and repeated scans in the late phase without breaking the perflubutane microbubbles. Perflubutane is different than other US contrast agents, and can be used to provide a highly accurate diagnosis of HCC with CE-US.
The process of diagnosis of HCC with glycogen storage disease type 1a (GSD-1a) depends on the above-mentioned social conditions. If the patient can be examined with EOB-MRI and CE-US with perflubutane with a skilled operator, we think it is better to examine alternately CE-US with EOB-MRI.
There is a shortage of information regarding the findings of HCC and hepatic adenomas in patients with GSD-1a examined by various abdominal imaging modalities. Experience with more cases of HCC with both CE-US with perflubutane and EOB-MRI with GSD-1a is needed.
